Biosimilar Development Editorial Board

Source: Biosimilar Development

Molly Burich, Director, Public Policy: Biosimilars and Reimbursement, Boehringer Ingelheim

Hubert C. Chen, MD
Chief Medical and Science Officer,
Pfenex

Hillel Cohen,
Executive Director,
Scientific Affairs,
Sandoz

Edric Engert, Managing Director, Abraxeolus Consulting

Erin Federman, Head of Biologics, Europe, Mylan

Francois-Xavier Frapaise, M.D., ClinExcel

Kavya Gopal,
Head of Specialty, Sandoz UK
Chair, British Biosimilars Assoc.

Ruediger Jankowsky,
Managing Director,
Cinfa Biotech

HoUng Kim,
Head of Strategy and
Operations,
Celltrion

Brian Lehman, MBA, MHA, RPh., Director, Medical Account Management and Strategic Alliances, Sandoz

Rick Lozano, VP, Biosimilars & Integrated Business Development, AmerisourceBergen

Julie Maréchal-Jamil, Director Biosimilars Policy & Science,
Medicines for Europe

Pankaj Mohan, CEO, Oncobiologics

Valerie Mulligan, VP, Global Regulatory CMC and Growth Markets, Branded Regulatory Affairs, Teva

Sue Naeyaert, Global Head of Pricing, Market Access, Government Affairs and Policy, Biosimilars, Fresenius Kabi SwissBioSim

Don Stewart,
CEO,
PlantForm